Introduction {#S1}
============

Neuropathic pain (NP) is caused by damage or disease affecting the somatosensory nervous system (SSNS) ([@B42]; [@B127]). NP may be connected with aberrant sensations, known as dysesthesia, or pain from usually non-painful stimuli, called allodynia. The SSNS plays a pivotal role in the transfer of noxious stimuli to the central nervous system (CNS) under normal circumstances ([@B129]). Therefore, lesion of the SSNS leads to the innervations of nerve cells stopping and causes pain with or without a sensory hypersensitivity event in the painful region ([@B89]). Furthermore, an injury in the SSNS could reveal itself as negative sensory symptoms or positive sensory symptoms. The positive sensory symptoms occur because of the regeneration as well as disinhibition of the nerve cells, whereas the negative sensory symptoms occur owing to the partial or complete loss of input to the nervous system ([@B156]; [@B198]). Moreover, positive symptoms can be either spontaneous or stimulus-induced.

Paresthesia (i.e., aberrant sensations of the skin including tingling, chilling, numbness, burning, and pricking), spontaneous or shooting stimulus-independent pain, as well as electric shock-like sensations are involved in spontaneous positive symptoms; whereas, stimulus-induced positive symptoms of neuropathy include allodynic and hyperalgesia pain ([@B146]; [@B23]). On the other hand, hypoesthesia (i.e., decreased sensations to non-painful stimuli), hypoalgesia (i.e., decreased sensations to toxic stimuli), pallhypesthesia (i.e., decreased sensations to vibration), and thermohypoesthesia (i.e., decreased sensations to cold/warm stimuli) are negative symptoms of NP ([@B89]; [@B171]).

Many studies have revealed the prospective efficacy of phenytoin, mexiletine, dextromethorphan, tricyclic anti-depressants, gabapentin, tramadol, pregabalin, opioids, and lamotrigine for painful sensory neuropathy ([@B77]; [@B15]). Conversely, these treatments cause a 30--50% decline in pain and are frequently restricted owing to their noticeable adverse effects, with dominant sedative action. Nowadays, natural products like plant secondary metabolites are widely used to treat several chronic diseases due to their limited adverse effects as well as high efficacy ([@B184], [@B182]; [@B22]; [@B151]; [@B168]; [@B21]). Flavonoids are a broad group of secondary metabolites, extensively found in many fruits, vegetables, wine, cocoa, and tea ([@B39]; [@B53]). Flavonoids are recognized to have antioxidant, analgesic, and anti-inflammatory properties ([@B190]). Moreover, these effects are associated with the suppression of nuclear factor kappa B (NF-κB)-dependent pro-inflammatory cytokines ([@B25]), vascular endothelial growth factor, intercellular adhesion molecule 1, signal transducer and activator of transcription 3 ([@B195]), and activation of antioxidant transcription factor including nuclear factor erythroid 2-related factor 2 (Nrf2) ([@B25]).

Numerous flavonoids have been demonstrated to be safe natural alternative treatments against neuropathic pain, oxidative stress, and neuroinflammatory diseases ([@B17]; [@B143]; [@B11]; [@B30]; [@B65]). Hence, flavonoids are considered as multi-target drugs, which elucidate their wide range of actions. Here, we have reviewed the recent studies on the promising effects of flavonoids for the treatment of NP.

Mechanisms of Neuropathic Pain {#S2}
==============================

Copious research in animal models have delivered some hint as to the pathophysiological mechanisms that produce NP, which involves both central and peripheral mechanisms ([@B19]; [@B29]; [@B64]) as shown in [Figure 1](#F1){ref-type="fig"}. Furthermore, the peripheral sensitization is performed through unmyelinated C- as well as finely myelinated Aδ-primary afferent neurons, which usually produce the sensation of pain in response to noxious stimuli. Conversely, the peripheral nerve injuries sensitize these neurons that develop a spontaneous activity. Moreover, these injuries result in significant alterations on the molecular and cellular levels activating the nerve cells ([@B19]).

![The outlines of the mechanism of neuropathic pain from nerve damage with probable clinical interventions. Nerve damage leads to peripheral nerve injury as well as spinal cord injury (central). The peripheral sensitization and hyperexcitability take place due to the peripheral nerve injury. Furthermore, the hyperexcitability of peripheral nociceptor leads to the generation of ectopic impulses, which plays a crucial role in producing spontaneous pain, superficial pain, and paroxysmal pain that ultimately leads to neuropathic pain. Conversely, selective sodium (Na) channel blockers such as lidocaine and carbamazepine inhibit the generation of ectopic impulses that reduces the sensation of neuropathic pain. On the other hand, the hyperexcitability of the central dorsal horn is caused by spinal cord injury that subsequently decreases intraspinal inhibitory interneurons, which finally leads to neuropathic pain. However, GABA agonists, including baclofen, inhibit the decreased intraspinal inhibitory interneurons that plays an essential role in reducing the sensation of neuropathic pain. DRG, dorsal root ganglion; Na, sodium.](fnins-14-00478-g001){#F1}

Overexpression of messenger ribonucleic acid (mRNA) for voltage-gated sodium channels in the primary afferent neurons is accountable for ectopic spontaneous activity after nerve damage. This event might cause the clustering of these channels, which declines the action potential threshold, leading to hypersensitivity. Therefore, sodium channel blockers, including lidocaine, demonstrate pain relief action in NP through this mechanism ([@B105]).

Peripheral nerve injury is also responsible for the upregulation of various receptor proteins. These receptors are usually found at the membranes of the primary afferents and are partly expressed during physiological conditions. Vanilloid receptors, including the transient receptor potential cation channel subfamily V member 1 (TrpV1), play a crucial role in the sensing of toxic heat exceeding 43°C ([@B138]), while transient receptor potential cation channel subfamily M (melastatin) member 8 (TRPM8) has been recognized as cold and menthol-sensitive which increase at temperature ranges from 8 to 28°C. Furthermore, the TRPM8 receptor is expressed in neurons that are small in diameter from the dorsal root ganglia ([@B119]). Nerve injuries can cause the upregulation of this channel, contributing to peripheral sensitization of C-nociceptors, which results in cold hyperalgesia ([@B202]).

In addition, acid-sensing ion channels are thought to take part in static mechanical hyperalgesia ([@B142]). In contrast, both α~1~- and α~2~-adrenoceptors situated on the cutaneous afferent fibers play an essential role in hypersensitivity from nerve damage ([@B20]). Furthermore, adrenergic sensitivity has extensively been expressed in complex regional pain syndromes II, post-traumatic neuralgias, and postherpetic neuralgias; while there is no sensitivity in the primary afferent neurons, which have been claimed in the case of polyneuropathies ([@B152]). Therefore, sympathetically-induced and temperature-mediated pain can be cured by inhibiting their relevant receptors on nociceptive neurons.

Ectopic activity is mediated by inflammation in both injured and contiguous typical primary afferent nociceptors, which are activated by nerve damage that generates proinflammatory cytokines, particularly tumor necrosis factor-α (TNF-α) ([@B160]). Furthermore, deep proximal, as well as paroxysmal pains are noticeable symptoms in the case of patients who have peripheral neuropathies, including human immunodeficiency virus-neuropathy. Increased concentrations of proinflammatory cytokines and cyclooxygenase-2 (COX-2) have been found in the nerve biopsy specimens of these patients ([@B109]).

CNS forms precise anatomical connections with the thalamus, brain stem, cortex, and spinal cord. Furthermore, these relations can connect the sensations that are produced in the high threshold primary afferents with the cortical areas of the CNS, which subsequently processes it into final painful sensations ([@B204]). The constant hyperactivity is produced by damaged nerves that are considered to be a causative factor for central sensitization, as well as triggering activity-dependent synaptic flexibility occurring inside the cortex. Moreover, various factors are involved in central sensitization such as excitatory amino acid, changes in ion channel kinetics, different synaptic modulators, pre- and post-synaptic activation of kinases, and increased bulk of ionotropic receptors.

Most of the patients who have peripheral as well as central neuropathy demonstrate dominant synaptic facilitation leading to hypersensitivity and allodynia ([@B29]). Additionally, peripheral nerve damage results in pre-synaptic changes such as alterations in the synthesis of neuromodulators, neurotransmitters, and modifications in the calcium channels density ([@B79]). In contrast, post-synaptic changes take place due to the increased density of receptors on account of increased synthesis of ion channels and scaffold proteins and the phosphorylation of N-methyl-D-aspartate (NMDA) subunits ([@B34]). These alterations also lead to aberrant expression of the mitogen-activated protein kinase system and Nav 1.3 ([@B71]; [@B93]). Furthermore, pathologically sensitized C-fibers sensitize neuropeptide substance P as well as a spinal dorsal horn (SDH) through the release of glutamate, which cannot be neglected. Subsequently, glutamate demonstrates an excitatory action by acting upon the postsynaptic NMDA receptor contributing to central sensitization ([@B191]). It has been observed that the involvement of loss of function of tonic γ-amino butyric acid-A (GABA~A~)-conciliated inhibition and enhanced excitatory neurotransmitters are caused by an induction of central sensitization, leading to peripheral hypersensitivity, specifically hyperalgesia and allodynia ([@B99]). When this sensitivity is developed, the generally harmless tactile stimuli can trigger Aβ as well as Aδ low threshold mechanoreceptors ([@B167]).

GABA and Neuropathic Pain {#S3}
=========================

The most abundant inhibitory neurotransmitter in the brain is GABA ([@B183]). GABA regulates diverse physiological functions such as anxiety, sleep, reward, and memory formation ([@B213]; [@B163]; [@B177]). GABA also regulates the excitatory action of neuronal cells of the CNS, assisting and maintaining the neural circuit's homeostasis. Previously, it has been described that the role of inhibitory neurons, especially in SDH, act and monitor transmission of pain via the periphery to greater intensities of the brain ([@B121]). After this, GABA was established to be the primary inhibitory neurotransmitters in the brain's SDH ([@B207]).

GABA, releasing from presynaptic neurons, acts postsynaptically with several receptors; G protein-coupled channels, GABA~A,~ GABA~B,~ as well as GABA~C,~ are ligand-gated ion channels ([@B63]). Generally, ionotropic GABA~A~ receptors are comprised of 5 heteropentameric subunits that form transmembrane protein complexes ([@B188]). Meanwhile, the α~1~β~2~γ~2~ subunit is thought to be the most dominant one in the human brain ([@B199]). GABA initiation stimulates the membrane penetrability to chloride and carbonate ions that produce a net inner flow of anions as well as resulting in hyperpolarization. Therefore, this hyperpolarizing post-synaptic reaction is known as inhibitory post-synaptic potential ([@B154]).

Physiologically, GABA-liberating interneurons impose a robust inhibitory regulation through dorsal horn neuronal cells. Besides, damage of these neurons might additionally stimulate the dominant sensitization of the models of peripheral partial nerve injury. In rodents, injury caused the reduction of GABA release from the spine, with reduced GABA-producing glutamic acid decarboxylase ([@B126]). However, in diseased conditions, an improved excitation state arises that is recognized as an enormous GABAergic neuronal loss or deterioration of interneurons. Therefore, an imbalance of this condition could culminate into several neurological as well as psychiatric diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, NP, and the collective role of inhibitory and excitatory neurons show a dynamic role in regulating many brain activities ([@B175]).

It has been found that peripheral and central sensitization causes nerve injury and NP. GABAergic interneuronal loss is considered to be the main contributor to persistent pain states ([@B27]). In the spinal cord, pharmacological inhibition of GABAergic neurotransmission causes hyperalgesia and allodynia ([@B69]; [@B90]). Likewise, GABA~A~ receptor blockage could prompt a behavioral reaction, which was revealed by electrophysiological studies ([@B84]). Furthermore, the GABAergic system impaired chronic NP in animals ([@B212]). As a result, spinal inhibitory neurotransmission may be appreciated as a pharmacological NP treatment.

Additionally, the crucial function of GABA in opioid-mediated antinociception has long been recognized ([@B135]). Also, agonists of GABA~A~ receptor-mediated antinociceptive activity have been recognized to stimulate or inhibit additional neurotransmitters ([@B118]). As a consequence, the agonists of the GABA receptor might play a dynamic role in considering chronic and acute pain ([@B118]). Incidentally, isoguvacine and muscimol, agonists of GABA~A~ receptors, are described to oppose nerve injury-stimulated tactile allodynia ([@B84]). These receptors are strictly linked to huge diameter afferents involved in innocuous sensation ([@B141]; [@B159]; [@B147]; [@B14]; [@B149]; [@B174]). Pharmacological as well as behavioral examinations have stated that a single or continuous intrathecal GABA response to spinal cord or GABA liberating cells reduce NP ([@B51], [@B52]; [@B166]; [@B115]). In addition, spinal GABA~A~ receptors inhibition shows annoying peripheral nerve injury connected to hyperalgesia ([@B208]).

In contrast, intrathecal administration of benzodiazepines (BDZs) and allosteric positive modulators of GABA~A~ receptors have been extensively used in sleep complaints, convulsions, anxiety, and analgesic activity ([@B173]). Even though it has analgesic properties, its usage in pain relief is limited due to sedation. Therefore, study is urgently needed in to GABAergic modulators which might play a prominent role in the attenuation of NP.

Flavonoids {#S4}
==========

Flavonoids are polyphenolic compounds found in fruits, flowers, barks, grains, vegetables, roots, tea, stems, and so on ([@B178]). Chemically, flavonoids are 15-carbon skeletons comprising of two benzene rings (A and B) linked via a heterocyclic pyrane ring (C) ([@B104]) as shown in [Figure 2](#F2){ref-type="fig"}. Flavonoids can be divided into diverse subgroups according to the carbon of the C ring whereon the B ring is connected as well as the oxidation and degrees of unsaturation of the C ring ([@B137]).

![Basic structure of flavonoids and their sub-classes.](fnins-14-00478-g002){#F2}

In 1930, a novel constituent derived from an orange was believed to be a vitamin and called vitamin P. It was subsequently proved to be a flavonoid, rutin, that played an essential role in the isolation as well as the study of the mechanisms of several individual flavonoids. In fact, several traditional medicines are mainly flavonoids. In past centuries, *Tanacetum parthenium* has been used as a prophylactic drug in the treatment of migraine, while *Matricaria recutita*, chamomile flowers, has been used as a tranquilizer for many decades, with both comprising of the active constituent apigenin ([@B86]). Moreover, linden flowers, *Tilia sp. Tiliaceae*, have been used as sedative agents, and *Calluna vulgaris* might serve as a nerve-calming medicine, which has active components of kaempferol and quercetin ([@B4]). Apart from the separation of natural flavonoids, several synthetic and semi-synthetic products have been synthesized and separated for their therapeutic potential ([@B45]). Up to now, 6000 diverse flavonoids have been isolated. Flavonoid compounds show different biological effects, such as neuroprotective ([@B36]; [@B187]; [@B185]; [@B211]), antifungal ([@B8]), antimicrobial ([@B45]; [@B66]), anticancer ([@B110]; [@B1]), anti-inflammatory ([@B200]; [@B22]), anxiolytic ([@B133]), antioxidant ([@B78]; [@B189]), antiviral ([@B134]; [@B46]), cardioprotective ([@B210]; [@B114]), and antinociceptive activities ([@B201]; [@B83], [@B82]).

Role of Flavonoid on Ionotropic GABA~A~ Receptors {#S5}
=================================================

Flavonoids are widely targeted for their peripheral events; though, their selective affinity for GABA~A~ receptors has extensively been demonstrated in studies using bovine and rat brain membrane binding analyses ([@B81]). Numerous behavioral tests have also widely been performed, which confirm the sedative effects of flavonoids in an animal model of anxiety that was devoid of the additional side effects of BDZs ([@B67]). Remarkably, negative, positive, and neutral allosteric modulatory flavonoid actions of an extensive variety of ionotropic GABA receptors have been focused on and intensely supported through enormous evidence. In the 1990s, flavonoids had been well-defined as a novel family of BDZ receptor ligands ([@B120]; [@B116]). Typically, they were believed to be acting upon BDZ receptors, as well as many synthetic flavonoids having a remarkable affinity for BDZ binding site ([@B209]), until they were claimed to be insensitive to the BDZ receptor antagonist, flumazenil, therefore focusing a distinctive site of action ([@B75]).

It has been found that the replacement at 6- or 3′-positions of flavones with an electronegative functional group improved the affinity toward the receptors of BDZ ([@B136]). Moreover, GABA ratios were measured by the impact of ligand binding on the GABA binding site. These ratios displayed that flavones showed substantial biological actions at BDZ receptors ([@B75]). 6-Bromo-3′-nitroflavone, 6-chloro-3′-nitroflavone, and 6-bromoflavone with a GABA ratio of 1.38, 2.0, and 1.6--2.0 were demonstrated as a partial agonist, an antagonist, and full agonist at these receptors respectively ([@B117]; [@B203]; [@B196]).

GABA~A~ receptors were enhanced by the flux of chloride ion that deliver a robust inhibitory effect via positive ionotropic modulators. As a result, these modulators are the strongest candidates for the management of CNS-associated diseases such as generalized anxiety, seizure disorders, sleep disturbances, panic disorders, muscle spasms, and NP ([@B150]). Furthermore, flavonoids might act upon a new binding site, excluding the classical BDZ binding site, which plays a pivotal role in searching for novel therapeutic candidates with limited adverse effects ([@B150]). Incidentally, 6-methoxyflavonone has been described to act as a positive allosteric modulator at α1β2γ2L and α2β2γ2L subunits of GABA~A~ receptors ([@B72]).

The substitution at 6-position on flavones is linked to its role in recombinant GABA~A~ receptors. 6-Hydroxyflavone showed a remarkable effect at the flumazenil-sensitive BDZ site ([@B148]). Furthermore, 6-methoxyflavone and 6-methoxyflavanone have been claimed to display anti-allodynic effects in cisplatin- and streptozotocin-stimulated NP models ([@B5]; [@B155]). Therefore, these defensive properties against NP have been recognized to cause allosteric positive modulatory effects on opioid and GABA~A~ receptors ([@B5]).

Additionally, myrcitin and baicalin exerted antiallodynic effects in sciatic nerve ligation models ([@B35]; [@B122]). Besides, quercetin and rutin have widely been claimed to suppress oxaliplatin-mediated chronic peripheral neuropathic pain ([@B17]). Meanwhile, the antiallodynic potential of streptozotocin-induced painful diabetic neuropathy has been reported by naringin ([@B95]).

Role of Flavonoids in Different Neuropathic Pain Models {#S6}
=======================================================

Effect of Flavonoids on Diabetic Neuropathy {#S6.SS1}
-------------------------------------------

NP is arduous to treat properly and is related to the remarkable impairment of health conditions as well as economic problems ([@B132]; [@B106]). Diabetic neuropathy is one of the most common causes of neuropathy and affects about 382 million people in the world ([@B26]). Furthermore, genistein ([@B193]), luteolin ([@B107]), catechin ([@B2]), rutin ([@B169]), and pelargonidin ([@B125]) have been revealed to decrease the levels of malondialdehyde (MDA) in animal models of diabetes. Moreover, MDA serves as a key biomarker for lipid damage as well as oxidative stress that can be caused by free radicals. In diabetic patients, the increased level of MDA has widely been observed in the serum as well as other tissues, which significantly affects the peripheral nerves ([@B54]; [@B139]). Some flavonoids, such as genistein ([@B193]), naringenin ([@B7]), luteolin ([@B107]), hesperidin, catechin ([@B2]), kaempferol ([@B98]), fisetin ([@B215]), rutin ([@B169]), and morin ([@B18]) have been shown to reduce the ROS level by increasing the level of diverse antioxidative enzymes including glutathione peroxidase, reduced glutathione peroxidase, superoxide dismutase, glutathione reductase, and catalase in various tissues such as the liver, sciatic nerve, and brain of diabetic animals ([Table 1](#T1){ref-type="table"}). In the diabetic animal model, rutin, luteolin, and morin have been demonstrated to raise the expression of Nrf2 as well as its downstream effector's heme oxygenase-1 (HO-1) in nerve tissues. Numerous studies have found that Nrf-2/HO-1 could fight against oxidative stress-mediated neuroinflammation and nerve damage in diabetic animal models ([@B32]; [@B3]; [@B103]). Moreover, kaempferol decreased advanced glycation end products and epigallocatechin gallate (EGCG) causes a reduction of 8-hydroxy-2-deoxyguanosine, which is considered as the major form of free radical-mediated oxidative stress in the nucleus and mitochondria ([@B192]). It has also been found that in the diabetic animal model, genistein and naringenin raised nerve growth factor (NGF) in sciatic nerves ([@B21]). Therefore, NGF servesas the survival and life maintenance of the neurons.

###### 

Promising studies of flavonoids for the management of neuropathic pain.

  Flavonoids                     Species/studied materials                                    Experimental model                                               Dose                                                                      Route of administration                            Effects                                                                                                                                                                                              References
  ------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Genistein                      C57BL/6J male mice                                           Chronic constriction sciatic nerve injury                        1, 3, 7.5, 15, and 30 mg/kg                                               Subcutaneous injection                             Ameliorate painful neuropathy by decreasing the mRNA expressions of IL-1β and IL-6 in sciatic nerve as well as protein expression of IL-1β in dorsal root ganglion and spinal cord                   [@B194]
                                 Male C57BL/6J mice                                           Streptozotocin-induced diabetic                                  3 and 6 mg/kg                                                             Subcutaneous injection                             Ameliorates diabetic peripheral neuropathy by inhibiting proinflammatory cytokine and the overproduction of reactive oxygen species, as well as restored the NGF content in diabetic sciatic nerve   [@B193]
                                 Male Sprague-Dawley rats                                     High-fat diet                                                    4 and 8 mg/kg/day                                                         Intragastrical                                     Decreases the levels of TNF-α and IL-6 in serum that produce anti-inflammatory actions                                                                                                               [@B92]
  Quercetin                      Male albino mice                                             Streptozotocin-induced diabetic                                  50 and 100 mg/kg                                                          Oral                                               Antinociceptive activity via the modulation of opioidergic mechanism that attenuates diabetic neuropathic pain                                                                                       [@B9]
                                 Male Sprague−Dawley rats                                     Streptozotocin-induced diabetic                                  10 mg/kg                                                                  Oral                                               Effective in diabetic neuropathy                                                                                                                                                                     [@B10]
                                 Male Sprague-Dawley rats and mice                            Paclitaxel-induced neuropathic pain                              20 and 60 mg/kg -- *in vivo* and 3, 10, 30 μM/L -- *in vitro*             Intraperitoneal injection                          Ameliorates neuropathic pain by decreasing the levels of protein kinase C (PKC)ε and TrpV1 in the spinal cord dorsal horns and dorsal root ganglions                                                 [@B62]
  Quercetin and rutin            Male Swiss mice                                              Oxaliplatin-induced peripheral neuropathy                        Rutin and quercetin (25, 50, and 100 mg/kg)                               Intraperitoneal injection                          Ameliorates peripheral neuropathy                                                                                                                                                                    [@B17]
  Myricitrin                     Adult Swiss mice                                             Partial Sciatic Nerve Ligation                                   30 mg/kg                                                                  Intraperitoneal injection                          Antinociceptive activity via the inhibition of PKC and nitric oxide cell signaling                                                                                                                   [@B122]
                                 Adult male Wistar rats                                       Spinal nerve ligation                                            0.1, 1 and 10 mg/kg                                                       Intraperitoneal injection                          Reduces neuropathic pain that might be related to its PKC-induced decrease of voltage-gated calcium channel currents in dorsal root ganglia neurons                                                  [@B70]
  Epigallocatechin gallate       Adult male Wistar rats                                       Alcoholic neuropathy                                             25, 50, 100 mg/kg                                                         Oral                                               Reduces neuropathic pain through the modulation of oxido-inflammatory pathway                                                                                                                        [@B170]
                                 Male Sprague-Dawley rats                                     Chronic constriction injury                                      1 mg/kg                                                                   Intrathecal injection                              Ameliorates neuropathic pain through the suppression of TLR4 signal pathway that reduces the expressions of NF-κB, IL-1β and TNF-α                                                                   [@B102]
                                 Male Wistar rats                                             Streptozotocin-induced diabetic                                  2 g/L                                                                     Oral gavage                                        Ameliorates diabetic neuropathy by preventing oxidative stress                                                                                                                                       [@B145]
  Puerarin                       Male Sprague-Dawley rats                                     Chronic constriction injury                                      100 mg/kg/day                                                             Intraperitoneal injection                          Reduces neuropathic pain through the P2X3 receptors in dorsal root ganglion neurons                                                                                                                  [@B206]
                                 Male Sprague-Dawley rats                                     Chronic constriction injury                                      4, 20, and 100 nM                                                         Intrathecal injection                              Reduces neuropathic pain by the inhibition of spinal NF-κB activation and the upregulation of cytokines                                                                                              [@B111]
  2″− O− rhamnosylswertisin      Female Swiss and C57/BL6 mice                                Partial Sciatic Nerve Ligation                                   125, 250 or 500 mg/kg                                                     Oral                                               Antinociceptive activity by reducing the neutrophil migration and IL-1β levels                                                                                                                       [@B144]
  Naringin                       Adult male Wistar rats                                       Streptozotocin-induced diabetic                                  20, 40, and 80 mg/kg                                                      Oral                                               Reduces neuropathic pain by down−regulation of cytokine including TNF-α                                                                                                                              [@B112]
                                 Wistar rats.                                                 Cisplatin-Induced Cognitive Dysfunction                          25, 50, and 100 mg/kg                                                     Oral gavage                                        Ameliorates neuropathic pain through the involvement of oxidative-stress-mediated inflammatory signaling                                                                                             [@B38]
                                 Male Wistar rats                                             Streptozotocin-induced diabetic                                  40 and 80 mg/kg                                                           Intraperitoneal injection                          Ameliorates diabetic neuropathy by downregulation of free radical, cytokine mediator including TNF-α                                                                                                 [@B95]
                                 Male Wister albino rats                                      Streptozotocin-induced diabetic                                  25 and 50 mg/kg/day                                                       Intraperitoneal injection                          Ameliorates diabetic neuropathy through its antioxidant and anti-inflammatory properties                                                                                                             [@B7]
  Icariin                        Male Sprague- Dawley rats                                    Paclitaxel-induced neuroinflammation and peripheral neuropathy   25, 50, and 100 mg/kg                                                     Intrathecal injection                              Reduces neuropathic pain by the level of TNF-α, IL-1β, and IL-6, astrocytes, NF-κB (p65) phosphorylation in spinal cord                                                                              [@B68]
  6-Methoxyflavone               Male Sprague- Dawley rats                                    Chemotherapy-induced peripheral neuropathy                       25, 50 and 75 mg/kg                                                       Intraperitoneal injection                          Reduces neuropathic pain                                                                                                                                                                             [@B155]
                                 Female Sprague- Dawley rats and BALB/c mice                  Streptozotocin-induced diabetic                                  10 and 30 mg/kg                                                           Intraperitoneal injection                          Attenuates neuropathic pain through interactions with the GABAergic and opioidergic systems                                                                                                          [@B5]
  Catechin                       Male Sprague- Dawley rats                                    Streptozotocin-induced diabetic                                  25 mg/kg and 50 mg/kg                                                     Intraperitoneal injection                          Attenuation of diabetic autonomic neuropathy through the improvement in antioxidant enzymes in vagus nerves                                                                                          [@B2]
  Morin                          Male Sprague- Dawley rats                                    Streptozotocin-induced diabetic                                  50 and 100 mg/kg -- *in vivo*, 10 and 20 μM -- *in vitro*                 Oral gavage                                        Reduces diabetic neuropathy by inhibiting NF−κB−mediated neuroinflammation and increasing Nrf2−mediated antioxidant defenses in high glucose−induced N2A cells                                       [@B18]
                                 Male Sprague- Dawley rats                                    Chronic constriction injury                                      15 and 30 mg/kg                                                           Oral gavage                                        Ameliorates neuropathic pain by decreasing the inflammatory markers (PARP, iNOS, COX-2, NF-κB and phospho-NF-κB, TNF-α, and IL-6) in the spinal cord                                                 [@B100]
  Kaempferol                     Male Wistar rats                                             Streptozotocin-induced diabetic                                  5 and 10 mg/kg                                                                                                               Reduces diabetic neuropathy by attenuating oxidative stress-mediated release of pro-inflammatory cytokines                                                                                           [@B98]
  Rutin                          Male Sprague- Dawley rats                                    Streptozotocin-induced diabetic                                  5, 25, and 50 mg/kg                                                       Intraperitoneal injection                          Ameliorates diabetic neuropathy through the up-regulation of the expression of Nrf2                                                                                                                  [@B169]
  Baicalin                       Male Sprague- Dawley rats                                    Streptozotocin-induced diabetic                                  10, 20, and 40 μg/kg                                                      Intraperitoneal injection                          Analgesic activity in diabetic neuropathic pain through transient receptor potential vanilloid 1                                                                                                     [@B108]
                                 C57Bl6/J mice                                                Streptozotocin-induced diabetic                                  30 mg/kg                                                                  Intraperitoneal injection                          Reduces diabetic peripheral neuropathy via the suppression of oxidative-nitrosative stress as well as p38MAPK activation                                                                             [@B164]
  Luteolin                       Male Sprague- Dawley rats                                    Streptozotocin-induced diabetic                                  50, 100, and 200 mg/kg                                                    Intraperitoneal injection                          Ameliorates diabetic neuropathy through the up-regulation of the expression of Nrf2                                                                                                                  [@B107]
                                 Male Sprague- Dawley rats                                    Chronic constriction injury                                      0.1--1.5 mg                                                               Intrathecal or intracerebroventricular injection   Reduces mechanical and cold hyperalgesia by activating GABA~A~ receptors in a flumazenil-insensitive manner as well as μ-opioid receptors in the spinal cord                                         [@B76]
  Fisetin                        Male C57BL/6J mice                                           Chronic constriction injury                                      10 mg/kg                                                                  Oral gavage                                        Ameliorates chronic neuropathic pain                                                                                                                                                                 [@B215]
                                 Male C57BL/6J mice                                           Chronic constriction injury                                      5, 15 and 45 mg/kg                                                        Oral gavage                                        Exerts antinociceptive activity through the serotonergic system (coupled with 5-HT7)                                                                                                                 [@B215]
  Diosmin                        Male Swiss mice                                              Chronic constriction injury                                      1, 10 mg/kg                                                               Intraperitoneal injection                          Ameliorates neuropathic pain by activating the NO/cGMP/PKG/KATP channel signaling                                                                                                                    [@B24]
  Hesperidin                     Sprague Dawley rats                                          Streptozotocin-induced diabetic                                  25, 50 and 100 mg/kg                                                      Oral gavage                                        Reduces diabetic neuropathy by down-regulating the production of free radical, release of cytokines (TNF-α and IL-1β) and elevation in membrane bound enzyme                                         [@B197]
  Diosmin and hesperidin         Male Wistar rats                                             Chronic constriction injury                                      Hesperidin (10, 100, 316.2, 562.3, 1000 mg/kg); Diosmin (10, 100 mg/kg)   Intraperitoneal injection                          Ameliorates neuropathic pain by the modulation of D2 dopamine, and opioids receptors                                                                                                                 [@B31]
  Pelargonidin                   Male Albino Wistar rats                                      Streptozotocin-induced diabetic                                  10 mg/kg                                                                  Oral gavage                                        Ameliorates diabetic neuropathic hyperalgesia via attenuation of oxidative stress                                                                                                                    [@B125]
  Isoorientin                    Male pathogen-free Institute of Cancer Research (ICR) mice   Chronic constriction injury                                      7.5, 15, and 30 mg/kg                                                     Intragastrical                                     Ameliorates neuropathic pain by decreasing the expression of IL-6, IL-1β, and TNF-α levels                                                                                                           [@B214]
  Grape seed proanthocyanidins   Wistar rats                                                  Chronic constriction injury                                      100 and 200 mg/kg                                                         Oral gavage                                        Anti-nociceptive and anti-inflammatory effect by inhibiting the inflammatory pathways                                                                                                                [@B96]

Diabetic neuropathy in animal models has widely been marked by evaluating behavioral signs, such as chemical, mechanical, thermal hyperalgesia, and tactile allodynia ([@B140]). It has also been observed that flavonoids considerably downregulated thermal, mechanical, chemical hyperalgesia, and tactile allodynia in diabetic animal models ([Figure 3](#F3){ref-type="fig"}). A number of flavonoids including fisetin ([@B215]), baicalin ([@B108]), naringenin ([@B7]), pelargonidin ([@B125]), rutin ([@B169]), naringin ([@B95]), hesperidin ([@B197]), and luteolin ([@B107]) reduced diabetes-mediated thermal hyperalgesia, although kaempferol ([@B98]), EGCG ([@B145]), rutin ([@B169]), naringenin ([@B7]), luteolin ([@B107]), morin ([@B18]), and naringin ([@B95]) attenuated mechanical hyperalgesia ([Figure 3](#F3){ref-type="fig"}). Furthermore, fisetin ([@B215]), baicalein ([@B108]), hesperidin ([@B197]), morin ([@B18]), and puerarin ([@B111]) ameliorated mechanical allodynia, while naringin ([@B95]) and genistein ([@B193]) decreased mechano-tactile allodynia, and rutin ([@B169]) and luteolin ([@B107]) improved cold allodynia. Numerous investigations have demonstrated that short term diabetes mediated mechanical, chemical, and thermal hyperalgesia ([@B50]; [@B60]), however chronic diabetes induces mechanical and thermal hypoalgesia ([@B28]). Besides, baicalein attenuated thermal hypoalgesia ([@B164]).
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Effect of Flavonoids on Chemotherapy-Induced Peripheral Neuropathy {#S6.SS2}
------------------------------------------------------------------

The use of diverse chemotherapeutic agents and other anticancer drugs leads to the impairment of the peripheral nerves. Chemotherapy-induced peripheral neuropathy (CIPN) is another form of neuropathy caused by anticancer drugs ([@B80]). Platinum compounds are extensively used in the management of several solid tumors. Oxaliplatin, a third-generation platinum agent, plays a pivotal role in diminishing antitumoral resistance with noticeable cytotoxicity ([@B12]; [@B165]). It has been observed that ([@B17]) rutin and quercetin suppressed oxaliplatin-mediated mechanical as well as cold nociceptive thresholds. In a study by [@B153] it was demonstrated that rutin and nanoemulsion of quercetin ameliorated oxaliplatin-mediated mechanical allodynia. According to the study by [@B155] 6-methoxyflavone showed antinociceptive activity in a rat model of CIPN ([Table 1](#T1){ref-type="table"}). Hence, 6-methoxyflavone considerably reduced cisplatin-mediated mechanical allodynia by raising the paw withdrawal threshold as well as thermal hypoalgesia ([Figure 3](#F3){ref-type="fig"}) by improving the paw thermal threshold.

Effect of Flavonoids on Sciatic Nerve Chronic Constriction Injury {#S6.SS3}
-----------------------------------------------------------------

Chronic constriction injury (CCI) is considered to be the most extensively studied model for chronic neuropathic pain. There are various symptoms of CCI-induced pain including hyperalgesia, allodynia, paraesthesia, dysesthesia, and spontaneous pain ([@B16]). Flavonoids including hesperidin ([@B31]), diosmin ([@B24]), and grape seed proanthocyanidins ([@B96]) decreased both mechanical and thermal hyperalgesia ([Figure 3](#F3){ref-type="fig"}). In contrast, other flavonoids including genistein ([@B194]), EGCG ([@B102]), EGCG-derived compounds ([@B205]), morin ([@B100]), and isoorientin ([@B214]) decreased only thermal hyperalgesia ([Table 1](#T1){ref-type="table"}). As compared to morphine and gabapentin, quercetin decreased the mechanical and thermal hypersensitivities to a greater extent ([@B40]). When quercetin was administered in a pre-injury condition, it exerted long term actions on mechanical hypersensitivity, which further suggests the antinociceptive properties of quercetin in the CCI model ([@B40]). Additionally, flavonoids including genistein ([@B194]), EGCG ([@B102]), puerarin ([@B111]), morin ([@B100]), and isoorientin ([@B214]) decreased CCI-mediated mechanical allodynia. On the other hand, cold allodynia was reduced by morin ([@B100]) and isoorientin ([@B214]). Although mechanical and cold hyperalgesia was reduced by luteolin, it did not affect thermal hyperalgesia ([@B76]). However, thermal hyperalgesia was decreased by fisetin, but did not affect the nociceptive sensitivity to mechanical stimuli ([@B215]).

An elevated level of nitro oxidative stress can cause DNA damage, which can cause the activation of poly-ADP ribose polymerase (PARP) ([Figure 4](#F4){ref-type="fig"}), which can further lead to PARP-induced DNA repair by transferring ADP-ribose units to the nuclear proteins. Nevertheless, activation of PARP can cause NF-κB activation, which can subsequently activate various inflammatory markers including interleukin (IL)-6, TNF-α, inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) ([@B131]; [@B161]) that lead to neuroinflammation ([Figure 4](#F4){ref-type="fig"}). Studies involving the CCI-induced neuropathic pain model revealed that flavonoids exert effects on various pro-inflammatory biomarkers ([@B24]; [Figure 3](#F3){ref-type="fig"}). A single administration of diosmin decreased the levels of mRNA expressions of IL-33/ST2 and IL-1β, while chronic administration decreased the mRNA expression level of TNF-α along with ST2, IL-33, and IL-1β. Furthermore, a single administration also decreased the expression levels of oligodendrocytes and microglia, whereas chronic treatment decreased astrocytes together with oligodendrocytes and microglia ([@B24]). Puerarin decreased the elevated immunoreactivity of glial fibrillary acidic protein and ionized calcium-binding adaptor protein-1, which are astroglia and microglial activation markers, successively ([@B111]). In the CCI-induced neuropathic pain model, morin decreased various inflammatory biomarkers including IL-6, TNF-α, phospho-NF-κB, NF-κB, COX-2, iNOS, and PARP ([@B100]). Deoxyribonucleic acid (DNA) damage was found to be increased due to the CCI-induced nerve injury, which resulted in PARP overactivation ([@B87]). It was found that overactivation of PARP caused bioenergetic failure because overactivity of PARP requires a high amount of nicotinamide adenine dinucleotide (NAD) during DNA repair, and finally, NAD synthesis also requires adenosine triphosphate (ATP), which can eventually lead to the disruption of biochemical processes that are dependent on ATP ([@B85]).
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Treatment with morin caused marked restoration of CCI-mediated reduction in the ATP levels and also restored the neuronal cells from the bioenergetic crisis ([@B100]). In a study, [@B102] revealed that treatment with EGCG reduced the mRNA and protein expressions of the toll-like receptor (TLR4) and its endogenous ligand HMGB1. It is known that TLR4 is a pattern recognition receptor and plays roles in the immune system and inflammatory diseases. When endogenous ligands bind with TLR4, it gets activated and stimulates the generation of pro-inflammatory cytokines by causing NF-κB activation ([@B88]; [@B6]). Furthermore, EGCG elevated the level of IL-10, reduced the downstream pro-inflammatory cytokines (i.e., TNF-α and IL-1β) of the TLR4 signaling pathway, and reduced the expression of NF-κB in the lumbar SDH of CCI rats ([@B102]). In the dorsal horn of the spinal cord, an EGCG-derived compound decreased the levels of mRNA and protein expressions of IL-6, NF-κB, IL-1β, and TNF-α ([@B205]). Administration of isoorientin and puerarin also decreased the level of CCI-induced pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α ([@B111]; [@B214]). Interestingly, genistein reduced the level of IL-1β expression in the spinal cord and dorsal root ganglion, while genistein also decreased mRNA expressions of both IL-6 and IL-1β in the sciatic nerve ([@B194]).

Effect of Flavonoids on Other Neuropathic Pain Signaling Pathways {#S6.SS4}
-----------------------------------------------------------------

Flavonoids show anti-inflammatory as well as antioxidant effects due to their action on GABA~A~ receptors ([@B75]). Maximum metabolic disorders are the result of oxidative stress. Along with exogenous factors, regular metabolism of oxygen inside the tissues and cells produce reactive oxygen species (ROS) and free radicals that steadily endanger them ([@B59]; [@B186]). Flavonoids are well-recognized for their antioxidant properties and are also confirmed to show beneficial effects in several chronic diseases, including neurodegenerative disease, diabetes, atherosclerosis, and cancer ([@B47]; [@B101]; [@B185]; [@B180], [@B181]). Moreover, certain flavonoids play a crucial role in the iron chelation thus stopping the development of free radicals ([@B130]; [@B55]). Rutin and epicatechin are shown to have the capability to be oxidized themselves through free radicals, producing a less reactive and stable species ([@B73]). Correspondingly, quercetin, a plant pigment flavonoid, prevents nitric oxide (NO)-mediated cell injury. A combination of NO and free radicals generates the enormously injurious peroxynitrite, which directly oxidizes low-density lipoprotein and plays a crucial role in the permanent damage of the cell membrane. Therefore, free radicals are scavenged by quercetin and restrained from reacting with NO, whereas, silibin reacts directly with NO ([@B48]; [@B158]). Mechanical allodynia induced by spinal nerve ligation (SNL) was found to be decreased by various flavonoids including myricetin ([@B70]), EGCG ([@B37]), and baicalein ([@B35]). SNL-induced thermal hyperalgesia was reduced by myricetin ([@B70]) and baicalein ([@B35]), while quercetin decreased both cold and thermal hyperalgesia in SNL rats ([@B91]). In addition to this, hesperetin and quercetin decreased partial sciatic nerve ligation-stimulated neuropathic pain and spared nerve injury ([Figure 3](#F3){ref-type="fig"}; [@B13]; [@B128]).

Physiologically, xanthine dehydrogenase plays an important role in the metabolism of xanthine to uric acid, however, this enzyme alters into xanthine oxidase in the case of ischemic-reperfusion, which works as a precursor of free radicals. There are various flavonoids, such as quercetin, silibinin, and luteolin, that are recognized to work as antioxidants through stopping xanthine oxidase ([@B33]; [@B157]). Similarly, reperfusion is also caused by the mobilization of leucocytes producing the subsequent release of inflammatory mediators as well as cytotoxic oxidants, which provokes the complement system. Many flavonoids play a key role in the immobilization of leucocytes, eventually resulting in a decline in the serum complement system as well as inflammation ([@B61]; [@B57]). It has been observed that the connection of the same pathophysiological mechanisms takes place with both NP of peripheral origin and inflammation. Both kinds of pathologies express as hyperalgesia and allodynia ([@B41]; [@B49]; [@B94]). Moreover, inflammatory cells infiltration and their main secretory products, including cytokines and arachidonic acid, affect peripheral nerve damage, which is accountable for the production and maintenance of the constant pain ([@B172]; [@B43]; [@B113]). When cytokines such as IL-1, IL-6, and TNF-α were injected into a rat paw, it would result in the initiation of thermal and mechanical hyperalgesia ([@B44]; [@B58]). On the other hand, the inhibition of TNF-α in the animal models with painful neuropathy led to the reduction of hyperalgesia ([@B162]). The release of cytokines also activates COX-2 dependent prostanoid releases. Furthermore, prostaglandins (PGs) also play a pivotal role in triggering inflammation that increases sensitivity to pain ([@B179]). It had been found that intrathecal injection of PGs such as PGE~2~ and PGF~2α~ triggered allodynia in conscious mice ([@B123], [@B124]), while intrathecal administration of PGD~2~ and PGE~2~ led to the initiation of hyperalgesia ([@B176]). Additionally, synthesis of NO and PG through COX-2 as well as iNOS is increased in the microglia on account of peripheral nerve damage, leading to hypersensitization ([@B74]). It is evident that flavonoids show anti-inflammatory activity both *in vitro* and *in vivo*. One of the imperative mechanisms of anti-inflammatory action is recognized by inhibiting eicosanoid producing enzymes such as phospholipase A2, lipoxygenases, and COX ([@B97]). Along with anti-inflammatory activity, flavonoids also block arachidonic acid metabolism ([@B56]).

Conclusion {#S7}
==========

In this review, we discuss the effects of flavonoids in improving different NP conditions and how flavonoids control diverse pain biomarkers in animal models of NP. Allosteric modulators at GABA~A~ receptors can alter either the affinity or efficacy of agonists including GABA, subsequently controlling their activity. Flavonoids are strong allosteric modulators and may serve as valuable candidates in the management of NP. Hence, it can be said that there is huge potentiality in flavonoids for the development of novel therapeutics agents for NP, however, further studies are needed.
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BDZ

:   benzodiazepines

CNS

:   central nervous system

CIPN

:   chemotherapy-induced peripheral neuropathy

CCI

:   chronic constriction injury

EGCG

:   epigallocatechin gallate

GABA

:   γ -amino butyric acid

MDA

:   malondialdehyde

NMDA

:   N-methyl -D-aspartate

NP

:   neuropathic pain

NF- κ B

:   nuclear factor kappa B

Nrf2

:   nuclear factor erythroid 2-related factor 2

SDH

:   spinal dorsal horn

SNL

:   spinal nerve ligation

SSNS

:   somatosensory nervous system.
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